Universal reference book for medicines
Product name: CERUCHAL ® (CERUCAL)

Active substance: metoclopramide

Type: Antiemetic drug of central action blocking dopamine receptors

Manufacturer: PLIVA HRVATSKA (Croatia)
Composition, form of production and packaging
The solution for intravenous and / or injection is
clear, colorless.

1 ml of 1 amp.

metoclopramide hydrochloride monohydrate 5.27 mg 10.54 mg,

in t.ch.
metoclopramide hydrochloride 5 mg 10 mg
Auxiliary substances: sodium sulfite, disodium edetate (disodium ethylenediaminetetraacetate), sodium chloride, water d / u.

2 ml - ampoules of colorless glass (5) - packings contour mesh (2) - packs cardboard.


Description of the drug approved by the manufacturer for the printed edition of 2010.


A specific blocker of dopamine receptors weakens the sensitivity of the visceral nerves that transmit pulses from the pyloric and duodenum to the vomiting center.Through the hypothalamus and the parasympathetic nervous system has a regulating and coordinating effect on the tone and motor activity of the upper gastrointestinal tract (including the tone of the lower digestive sphincter at rest).
Increases the tone of the stomach and intestines, accelerates the emptying of the stomach, reduces the hyperacid stasis, prevents pyloric and esophagal reflux, stimulates intestinal peristalsis.

V d is 2.2 - 3.4 l / kg.

Metabolised in the liver.
The half-life period is from 3 to 5 hours, with chronic renal failure - 14 hours. It is excreted by the kidneys during the first 24 hours in unchanged form and in the form of metabolites (about 80% and once taken dose). Easily penetrates the blood-brain barrier and is excreted in breast milk.

- vomiting and nausea of ​​various origins;

- atony and hypotension of the stomach and intestines (in particular, postoperative);

- biliary dyskinesia, reflux esophagitis, functional stenosis of the pylorus;

- to enhance peristalsis during radiocontrast studies of the gastrointestinal tract;

- paresis of the stomach in diabetes mellitus;

- as a means to facilitate duodenal sounding (to accelerate the emptying of the stomach and promote food through the small intestine).


In / m or slowly in / in.

Adults and adolescents older than 14 years: 1 ampoule (10 mg metoclopramide) 3-4 times a day.

Children from 3 to 14 years of age: The therapeutic dose is 0.1 mg metoclopramide / kg body weight, the maximum daily dose is 0.5 mg metoclopramide / kg body weight.

When the renal function is impaired, the dose of the drug is appropriately selected according to the severity of the renal dysfunction.

Creatinine clearance The dose of metoclopramide

up to 10 ml / min 10 mg once a day

from 11 to 60 ml / min daily dose of 15 mg divided into two doses (10 mg + 5 mg)

Prevention and treatment of nausea and vomiting caused by the use of cytostatics:

Scheme 1.

Short-term drop infusion (for 15 minutes) at a dose of 2 mg / kg half an hour before the start of treatment with cytostatic agent, and then after 1.5 hours, 3.5 hours, 5.5 hours and 8.5 hours after the use of cytostatics.

Scheme 2.

Continuous drip infusion at a dose of 1.0 or 0.5 μ / kg per hour, starting 2 hours before the application of the cytostatic agent, then at a dose of 0.5 or 0.25 mg / kg per hour for the next 24 hours after the application of the cytostatic agent.

Drip infusion is carried out briefly for 15 minutes after preliminary dilution of the dose of cerucal in 50 ml of the infusion solution.

The injectable solution of cerucal can be diluted with an isotonic solution of sodium chloride or 5% glucose solution.

Cerucal is used throughout the treatment period with cytostatic agents.


From the nervous system: sometimes there may be a feeling of fatigue, headaches, dizziness, a sense of fear, anxiety, depression, drowsiness, tinnitus;
in some cases, mainly in children, dyskinetic syndrome (involuntary tick-like twitching of the muscles of the face, neck or shoulders) can develop. Perhaps the appearance of extrapyramidal disorders: spasm of facial muscles, trismus, rhythmic protrusion of the tongue, bulbar type of speech, spasm of extraocular muscles (including oculogic crisis), spasmodic torticollis, opisthotonus, muscle hypertonia. Parkinsonism (tremor, twitching of muscles, limited mobility, risk of development in children and adolescents increases when the dose is exceeded 0.5 mg / kg / day) and late dyskinesia (in elderly patients with chronic renal insufficiency). In isolated cases, the development of severe neuroleptic syndrome is possible.
With prolonged treatment with cerucalom, elderly patients may develop symptoms of parkinsonism (tremor, twitching of muscles, limited mobility) and late dyskinesia.

From the side of the hematopoiesis system: agranulocytosis.

From the cardiovascular system: supraventricular tachycardia, hypotension, hypertension.

From the gastrointestinal tract: constipation, diarrhea, dry mouth.

On the part of the endocrine system: with prolonged use of the drug may occur gynecomastia (an increase in mammary glands in men), galactorrhea (spontaneous discharge of milk from the mammary glands) or menstrual irregularities;
When these phenomena develop, metoclopramide is canceled.

- hypersensitivity to metoclopramide;

- pheochromocytoma (possible hypertensive crisis, in connection with the release of catecholamines);

- intestinal obstruction, intestinal perforation and gastrointestinal bleeding;

- Prolactin-dependent tumor;

- Epilepsy and extrapyramidal movement disorders, the first trimester of pregnancy and lactation, the age of up to 2 years.

With caution: with arterial hypertension, violations of liver function, hypersensitivity to procaine and procainomid, children aged 2 to 14 years

During the 2nd and 3rd trimester of pregnancy, the drug is prescribed only for life indications.

Patients with reduced renal function medication is prescribed in reduced doses.

In connection with the sodium sulfite content, the drug should not be prescribed to patients with bronchial asthma with increased sensitivity to sulfite.


Contraindicated in the first trimester of pregnancy and lactation.

In the II and III trimesters of pregnancy, the drug is prescribed only for vital indications


Patients with reduced renal function medication is prescribed in reduced doses.
In patients with severe impairment of kidney function, follow the possible development of side effects, if they occur, the drug is canceled.

With caution apply this drug for violations of liver function.


Do not administer to children younger than 2 years.

Be wary appoint children aged 2 to 14 years.
Adolescents are monitored for the possible development of side effects, if they occur, the drug is canceled.

During the treatment period it is necessary to refrain from driving motor vehicles and practicing potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

In the process of treatment, alcohol consumption is prohibited.

In adolescents and in patients with severe impairment of kidney function, follow the possible development of side effects, if they occur, the drug is canceled.

It is not effective for vomiting of vestibular genesis.

Against the background of the use of metoclopramide, there are possible distortions of these laboratory parameters of liver function and determination of the concentration of aldosterone and prolactin in plasma.


Symptoms: drowsiness, confusion, irritability, anxiety, seizures, extrapyramidal movement disorders, cardiovascular system disorders with bradycardia and arterial hypo- or hypertension.
With mild forms of poisoning, symptoms disappear after 24 hours after drug withdrawal. Depending on the severity of the symptoms, it is recommended to establish monitoring of the vital functions of the patient. Deaths of poisoning in case of an overdose have not yet been identified.
Treatment: symptomatic.
Extrapyramidal disorders are eliminated by slow administration of biperidene (doses for adults 2.5 to 5 mg, should be followed by the manufacturer's recommendation). Possible use of diazepam.

Incompatible with infusion solutions that have an alkaline environment.

Reduction of the action of anticholinesterase agents.

Strengthens the absorption of antibiotics (tetracycline, ampicillin), paracetamol, levodopa, lithium and alcohol.

Reduces absorption of digoxin and cimetidine.

Strengthens the effect of alcohol and drugs, depressing the central nervous system.

It should not be used simultaneously with metoclopramide to prescribe neuroleptic drugs in order to avoid a possible increase in extrapyramidal disorders.

It can affect the effect of tricyclic antidepressants, monoamine oxidase (MAO) inhibitors and symptomatic agents.

Reduces the effectiveness of H 2 -gistaminoblockers.

Increased risk of hepatotoxicity when combined with hepatotoxic agents.

Reduces the effectiveness of pergolide, levodopa.

Increases the bioavailability of cyclosporine, which may require monitoring of its concentration.

Increases the concentration of bromocriptine.

With the simultaneous appointment of cerulek with thiamine (Vitamin B1), the latter rapidly disintegrates.


The drug is released by prescription.


List B.

The drug should be stored in a dark place at a temperature of no higher than 30 ° C.

Keep out of the reach of children.

Shelf life 5 years.
Do not use after the expiration date.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!